Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society

Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials

(2023) Faraidoon Haghdoost et al.   CEPHALALGIA

Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis

(2023) Roberta Messina et al.   CEPHALALGIA

Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study

(2022) Bo Hu et al.   JOURNAL OF HEADACHE AND PAIN

Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials

(2021) Zeya Yan et al.   JOURNAL OF HEADACHE AND PAIN

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials

(2021) Timothy R. Smith et al.   JOURNAL OF HEADACHE AND PAIN

Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis

(2021) Xing Wang et al.   Frontiers in Pharmacology

Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study

(2021) Shuu-Jiun Wang et al.   CEPHALALGIA

CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis

(2021) Florian Frank et al.   CEPHALALGIA

Chronic versus episodic migraine: The 15‐day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency

(2021) Ryotaro Ishii et al.   HEADACHE

Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients

(2021) Fumihiko Sakai et al.   HEADACHE

Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients

(2021) Fumihiko Sakai et al.   HEADACHE

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study

(2021) Takao Takeshima et al.   HEADACHE

Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial

(2021) Uwe Reuter et al.   CEPHALALGIA

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

(2020) Messoud Ashina et al.   CEPHALALGIA

Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study

(2020) Stewart J Tepper et al.   CEPHALALGIA

Efficacy and safety of eptinezumab in patients with chronic migraine

(2020) Richard B. Lipton et al.   NEUROLOGY

Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis

(2020) Yousef Waleed Alasad et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

(2020) Wim M Mulleners et al.   LANCET NEUROLOGY

Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial

(2019) David W Dodick et al.   CEPHALALGIA

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

(2019) Michel D Ferrari et al.   LANCET

RoB 2: a revised tool for assessing risk of bias in randomised trials

(2019) Jonathan A C Sterne et al.   BMJ-British Medical Journal

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults

(2019) Fumihiko Sakai et al.   HEADACHE

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

(2018) Vladimir Skljarevski et al.   CEPHALALGIA

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

(2018) David W Dodick et al.   CEPHALALGIA

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

(2018) David W. Dodick et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evaluation of Galcanezumab for the Prevention of Episodic Migraine

(2018) Virginia L. Stauffer et al.   JAMA Neurology

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention

(2018) Vladimir Skljarevski et al.   JAMA Neurology

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

(2018) Uwe Reuter et al.   LANCET

Galcanezumab in chronic migraine

(2018) Holland C. Detke et al.   NEUROLOGY

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

Fremanezumab for the Preventive Treatment of Chronic Migraine

(2017) Stephen D. Silberstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Hong Sun et al.   LANCET NEUROLOGY

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables

(2011) Gordon Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY